Category Archives: MS Treatment

WATCH TIME: 4 minutes Welcome to this special edition of Neurology News Network. Im Marco Meglio. Continue reading →

WALTHAM, Mass., May 29, 2024 /PRNewswire/ --The iConquerMS People-Powered Research Network (PPRN) (www.iConquerMS.org), a research initiative of the Accelerated Cure Project (ACP), is partnering with the Department of Veterans Affairs (VA), the digital therapy company GAIA AG, Charit Universitatsmedizin Berlin, the University Medical Center Gttingen, and Ordinal Data, Inc., on a four-year, large-scale clinical trial of online programs, or digital therapeutics, for treating fatigue in multiple sclerosis (MS). Continue reading →

WATCH TIME: 5 minutes "I do worry that the evobrutinib trial was a canary in the coal mine and is going to tell us something. Unfortunately, it was disappointing for at least the relapsing studies with these other Bruton tyrosine kinase inhibitors." Although there are several available high-efficacy therapies for patients living with multiple sclerosis (MS), many still experience significant disability worsening because of the limited effects of such drugs on central nervous system (CNS)-compartmentalized inflammation. Continue reading →

An estimated 2.8 million people worldwide have multiple sclerosis (MS). This autoimmune condition is the result of the immune system damaging parts of the nerves in the brain and spinal cord, which can lead to problems with movement, vision, balance and sensation. While many MS symptoms can be managed, there's currently no way to cure or prevent the condition Continue reading →

WATCH TIME: 4 minutes "This means to some extent that, the synthesis of immunoglobulins is actually decreasing to some extent, due to the immune reconstitution happening when you're taking the medication." Cladribine is an analog of deoxyadenosine that contains a substation of a chlorine atom for a hydrogen atom at position two of the purine ring, rendering it resistant to deamination by adenosine deaminase. The therapy, which has been approved for several years, mimics severe immunodeficiency disorder by selectively disrupting T-cell and B-cell immunity. Within cells, high cladribine concentrations increase the expression of deoxycytidine kinase, leading to lymphocyte apoptosis Continue reading →

New research findings presented at the Consortium of Multiple Sclerosis Centers 2024 Annual Meeting found that in utero exposure to ocrelizumab (Ocrevus; Genentech) was not associated with an increased risk of adverse pregnancy or infant outcomes compared with the epidemiologic background of both multiple sclerosis (MS) as well as the general population. Family planning is an important issue for many patients with MS, and newer medications are making pregnancy safer and more possible for this patient population. Continue reading →

Bengaluru: When Bengaluru resident Arun Mohan was diagnosed with multiple sclerosis over eight years ago, it pushed the sales executive to become a life wellness coach to extend support to people. Now, a member of the governing council and executive committee of the Multiple Sclerosis Society of India (MSSI)s Bengaluru chapter, Arun works to raise awareness about multiple sclerosis, a chronic neurological disorder occurring when the immune system mistakenly attacks healthy tissue in the central nervous system, which includes the brain and the spinal cord. Multiple sclerosis has no cure Continue reading →

Chlorthalidone has shown superiority in previous trials evaluating cardiovascular disease but is less commonly prescribed compared to hydrochlorothiazide, which has dominated the US market. The Diuretic Comparison Project (DCP) study aimed to provide clarity on their comparative efficacy. Continue reading →

People who start treatment with Tysabri (natalizumab) soon after being diagnosed with multiple sclerosis (MS) are at a lower risk of relapse in the long term compared with patients who start on less effective disease-modifying therapies (DMT), a study has found. Continue reading →

This is a video synopsis/summary of a panel discussion involving Ahmed Obeidat, MD, PhD; Riley Bove, MD; Stephen Krieger, MD; and Erin Longbrake, MD, PhD. In the discussion, the topic of treating multiple sclerosis (MS) in older individuals is explored. There's recognition that chronological age alone doesn't determine treatment decisions, as individuals' health status and disease mechanisms vary Continue reading →